Colgate Palmolive CO Form 4 insider transactions

John T Cahill, a Director of Colgate Palmolive Co, sold 4,170 shares of common stock on August 6, 2026 for $93.37 per share.

Noel R. Wallace, Chairman, President & CEO and a Director of Colgate Palmolive Co, sold 322,042 shares of common stock on August 4, 2026.

Colgate-Palmolive COO, Americas, Shane Grant, reported a transaction involving the withholding of shares for tax purposes on June 16, 2026.

Brian Newman, a Director at Colgate-Palmolive, received an annual stock grant and stock options as part of the company's incentive compensation plan.

Kimberly A. Nelson, a Director at Colgate-Palmolive, received an annual stock grant and stock options as part of the company's incentive compensation plan.

Martina Hundmejean, a Director at Colgate-Palmolive, received stock grants and options on May 11, 2026, as part of the company's incentive compensation plan.

Colgate-Palmolive director Martin C. Harris received stock grants and options as part of the company's annual incentive compensation plan.

Colgate-Palmolive reports on director Lorrie M. Norrington's acquisition of common stock and stock options as part of the company's incentive compensation plan.

Colgate-Palmolive director Lisa Edwards received an annual stock grant and stock options as part of the company's incentive compensation plan.

Colgate-Palmolive Director John T. Cahill was granted 2,075 shares of common stock and 2,424 stock options as part of the company's annual director compensation plan.

Colgate-Palmolive Director Christopher S. Boerner received an annual stock grant and stock options as part of the company's incentive compensation plan.

John P. Bilbrey, a Director at Colgate-Palmolive, received an annual stock grant and stock options on May 11, 2026, as part of the company's incentive compensation plan.

Colgate-Palmolive Chief People Officer Sally Massey reported a sale of 8,599 shares of common stock on May 7, 2026.

Colgate-Palmolive Director Lorrie M. Norrington acquired company stock through a deferred compensation plan.

Colgate-Palmolive Director Brian Newman acquired stock units valued at $89.05 each as part of a deferred compensation plan.

John P. Bilbrey, a Director at Colgate-Palmolive, acquired company stock through a deferred compensation plan.

Colgate-Palmolive Chief Growth Officer John Hazlin reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax liabilities.

Colgate-Palmolive's Chief Legal Officer and Secretary, Jennifer Daniels, reported the vesting of performance-based restricted stock units and subsequent tax-related share withholding.

Colgate-Palmolive's EVP and Controller, Gregory Malcolm, increased his direct beneficial ownership of company common stock through the vesting of performance-based restricted stock units.

Colgate-Palmolive's Chief Human Resources Officer, Sally Massey, reported the vesting of performance-based restricted stock units and subsequent tax-related share withholding.

Colgate-Palmolive's CFO, Stanley J. Sutula III, reported the vesting of performance-based restricted stock units and subsequent tax-related share withholding.

Colgate-Palmolive's COO, Panagiotis Tsourapas, reported the vesting of 25,742 performance-based restricted stock units and the disposition of 13,081 shares for tax purposes.

Colgate-Palmolive CEO Noel R. Wallace reported the vesting of 136,710 performance-based restricted stock units and the subsequent disposition of 68,252 shares for tax obligations.

Colgate-Palmolive's COO, Panagiotis Tsourapas, exercised stock options and subsequently sold a portion of the acquired common stock.

Colgate-Palmolive's EVP and Controller, Malcolm Gregory, exercised stock options and subsequently sold a portion of the acquired shares.

Colgate-Palmolive's Chief Human Resources Officer, Sally Massey, exercised stock options and subsequently sold shares on February 5, 2026.

Colgate-Palmolive's Chief Financial Officer, Stanley J. Sutula III, exercised stock options and subsequently sold 97,843 shares of common stock.

Colgate-Palmolive's Chief Legal Officer and Secretary, Jennifer Daniels, exercised stock options and subsequently sold an equal number of shares.

Colgate-Palmolive Chairman, President & CEO Noel R. Wallace sold 45,568 shares of common stock for approximately $4.28 million under a Rule 10b5-1 plan.

Colgate-Palmolive Director John P. Bilbrey acquired 301 shares of common stock by deferring a portion of his annual cash retainer.